

**Amendment to the Claims:**

The listing of claims will replace all prior versions, and listings of claims in the prior application.

**Listing of Claims:**

Claims 1 - 27 (Cancelled)

Claim 28 (New): A method of treating a disorder selected from the group consisting of:

a) a psychiatric disorder other than schizophrenia, a schizoaffective disorder, or a schizotypal disorder; and

b) a neurological disorder or a neurodegenerative disorder other than Huntington's disease

comprising administering to a subject a pharmaceutical preparation comprising EPA in an appropriately assimilable form, wherein of all the fatty acids present in the preparation at least 90% is in the form of EPA, and wherein less than 5% is in the form of docosahexaenoic acid (DHA).

Claim 29 (New): The method of claim 28, further comprising identifying the subject as an individual who is at risk from the disorder, suffering from the disorder, or exhibiting symptoms of the disorder.

Claim 30 (New): The method of claim 28, wherein of all the fatty acids present in the preparation at least 95%, is in the form of EPA.

Claim 31 (New): The method of claim 28, wherein of all the fatty acids present in the preparation less than 3% is in the form of docosahexaenoic acid (DHA).

Claim 32 (New): The method of claim 28, wherein among the other fatty acids present, other than docosahexaenoic acid (DHA) and EPA, there are less than 5% of each of AA or DPA-n-3, individually.

Claim 33 (New): The method of claim 28, wherein among the fatty acids present, other than docosahexaenoic acid (DHA) and EPA, there are less than 3% of each of AA or DPA-n-3, individually.

Claim 34: The method of claim 28, wherein the aggregate DHA, AA and/or DPA-n-3 content is less than 10% of the total fatty acids present.

Claim 35 (New): The method of claim 28, wherein the aggregate DHA, AA and/or DPA-n-3 content is less than 5% of the total fatty acids present.

Claim 36 (New): The method of claim 28, wherein the EPA is selected from group consisting of:

- a) ethyl-EPA;
- b) lithium EPA;
- c) mono-, di- and triglyceride EPA;

- d) an ester or salt of EPA;
- e) a free acid form of EPA; and
- f) an appropriate bioavailable derivative which raises EPA levels in the subject.

Claim 37 (New): The method of claim 28 wherein the EPA is in the form of a 2-substituted derivative or other derivative which reduces the rate of oxidation without impairing its biological activity.

Claim 38 (New): The method of claim 28, wherein the psychiatric disorder to be treated is depression.

Claim 39 (New): The method of claim 28, wherein the psychiatric disorder to be treated is bipolar disorder.

Claim 40 (New): The method of claim 28, wherein the psychiatric disorder to be treated is a sleep disorder.

Claim 41 (New): The method of claim 28 wherein the psychiatric disorder to be treated is an anxiety disorder, a panic disorder, a social phobia, or a combination thereof.

Claim 42 (New): The method of claim 28 wherein the psychiatric disorder to be treated is a personality disorder.

Claim 43 (New): The method of claim 28 wherein the psychiatric disorder to be treated is a conduct disorder, an attentional disorder, a hyperactivity disorder, or a combination thereof.

Claim 44 (New): The method of claim 28 wherein the neurological or neurodegenerative disorder to be treated is dementia.

Claim 45 (New): The method of claim 44, wherein the dementia is Alzheimer's disease, Lewy body disease, vascular dementia or a combination thereof.

Claim 46 (New): The method of claim 28, wherein the neurological disorder or neurodegenerative disorder to be treated is a trinucleotide repeat disease, spino-cerebellar ataxia, Friedreich's ataxia, or any other disease in this group, or a combination thereof.

Claim 47 (New): The method of claim 28, wherein the neurological disorder or neurodegenerative disorder to be treated is Parkinson's disease.

Claim 48 (New): The method of claim 28, wherein the neurological disorder or neurodegenerative disorder to be treated is multiple sclerosis.

Claim 49 (New): The method of claim 28, wherein the neurological disorder or neurodegenerative disorder to be treated is Motor Neuron disease, also known as amyotrophic lateral sclerosis.

Claim 50 (New): The method of claim 28, wherein the neurological disorder or neurodegenerative disorder to be treated is stroke.

Claim 51 (New): The method of claim 28, wherein the neurological disorder or neurodegenerative disorder to be treated is epilepsy.

Claim 52 (New): The method of claim 28, further comprising administering to the subject a pharmaceutical composition which is a psychiatric or neurological drug that acts on neurotransmitter metabolism or receptors.

Claim 53 (New): The method of claim 52, wherein the pharmaceutical composition is formulated together with the pharmaceutical preparation.

Claim 54 (New): The method of claim 52, wherein the pharmaceutical composition is present in a therapeutically effective amount.

Claim 55 (New): The method of claim 28, wherein the EPA is ethyl-EPA.

Claim 56 (New): The method of claim 28, wherein the EPA is lithium-EPA.

Claim 57 (New): The method of claim 28, wherein the EPA is present as a monoglyceride, a diglyceride, a triglyceride, or a combination thereof.

Claim 58 (New): The method of claim 28, wherein the EPA is an ester or a salt of EPA.

Claim 59 (New): The method of claim 28, wherein the EPA is a free acid form of EPA.

Claim 60 (New): The method of claim 28, wherein the pharmaceutical preparation comprising EPA is in capsule form.

Claim 61 (New): The method of claim 28, wherein the EPA is administered in a daily dose in the range of 0.05 to 50 g/day.

Claim 62 (New): The method of claim 28, wherein the EPA is administered in a daily dose in the range of 0.1 to 10 g/day.

Claim 63 (New): The method of claim 28, wherein the EPA is administered in a daily dose in the range of 0.5 to 5 g/day.

Claim 64 (New): The method of claim 28, wherein the EPA is administered in a daily dose in the range of about 1 to about 2 g/day.